Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) insider Shafique Virani sold 10,000 shares of the stock in a transaction dated Tuesday, January 17th. The stock was sold at an average price of $9.16, for a total transaction of $91,600.00. Following the sale, the insider now directly owns 73,160 shares in the company, valued at approximately $670,145.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Shafique Virani also recently made the following trade(s):
- On Thursday, December 15th, Shafique Virani sold 10,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $8.85, for a total transaction of $88,500.00.
- On Tuesday, November 15th, Shafique Virani sold 10,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $12.31, for a total transaction of $123,100.00.
Recursion Pharmaceuticals Trading Up 2.1 %
NASDAQ RXRX opened at $8.65 on Friday. Recursion Pharmaceuticals, Inc. has a 52 week low of $4.92 and a 52 week high of $14.18. The firm has a 50 day moving average of $8.70 and a two-hundred day moving average of $9.78.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in RXRX. Strs Ohio boosted its holdings in Recursion Pharmaceuticals by 41.8% in the second quarter. Strs Ohio now owns 20,700 shares of the company’s stock valued at $168,000 after purchasing an additional 6,100 shares in the last quarter. CWM LLC grew its position in shares of Recursion Pharmaceuticals by 99.3% in the 3rd quarter. CWM LLC now owns 8,990 shares of the company’s stock valued at $96,000 after buying an additional 4,480 shares during the last quarter. Trexquant Investment LP acquired a new stake in Recursion Pharmaceuticals during the 2nd quarter worth $442,000. Centaurus Financial Inc. purchased a new stake in Recursion Pharmaceuticals in the second quarter valued at $82,000. Finally, US Bancorp DE acquired a new position in Recursion Pharmaceuticals in the second quarter valued at $132,000. Hedge funds and other institutional investors own 63.62% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of research firms have recently weighed in on RXRX. The Goldman Sachs Group upped their price objective on Recursion Pharmaceuticals from $8.00 to $9.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 9th. SVB Leerink cut their price target on Recursion Pharmaceuticals from $10.00 to $9.00 and set a “market perform” rating on the stock in a report on Tuesday, October 25th.
Recursion Pharmaceuticals Company Profile
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis.
- Get a free copy of the StockNews.com research report on Recursion Pharmaceuticals (RXRX)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.